Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-02
2005-08-02
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S460000
Reexamination Certificate
active
06924305
ABSTRACT:
Compounds of the formula I, in which B1, B2, R1, R2, R6, R7, K1 and K2 are as defined in the description are novel effective tryp-tase inhibitors.
REFERENCES:
patent: 6489327 (2002-12-01), Bär et al.
patent: WO 95/32945 (1995-12-01), None
patent: WO 96/09297 (1996-03-01), None
patent: WO 98/04537 (1998-02-01), None
patent: WO 99/12918 (1999-03-01), None
patent: WO 99/24395 (1999-05-01), None
patent: WO 99/24407 (1999-05-01), None
patent: WO 99/40073 (1999-08-01), None
patent: WO 99/40083 (1999-08-01), None
patent: WO 00/14097 (2000-03-01), None
patent: WO 01/10845 (2001-02-01), None
patent: WO 01/10848 (2001-02-01), None
patent: WO 01/19809 (2001-03-01), None
patent: WO 01/46128 (2001-06-01), None
patent: WO 01/46168 (2001-06-01), None
Altana Pharma AG
Goldberg Joshua B.
Kifle Bruck
McGee Sheldon M.
Nath & Associates PLLC
LandOfFree
Diazocine derivatives and their use as tryptase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diazocine derivatives and their use as tryptase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diazocine derivatives and their use as tryptase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498807